Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy., PMID:40519935
Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies., PMID:40507880
Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors in vivo., PMID:40365291
Siglec-15 antibody-GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages., PMID:40216442
Siglec-15 is a putative receptor for porcine epidemic diarrhea virus infection., PMID:40172660
Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer., PMID:39940924
Screening and preparation of nanobodies for SIGLEC-15 detection., PMID:39880295
Targeting Siglec-15 mediates mitochondrial retrograde regulation of cervical cancer development., PMID:39756115
Siglec15 in blood system diseases: from bench to bedside., PMID:39697338
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer., PMID:39609852
Siglec15/TGF-β bispecific antibody mediates synergistic anti-tumor response against 4T1 triple negative breast cancer in mice., PMID:39553435
Expression of SIGLEC15 correlates with tumor immune infiltration, molecular subtypes, and breast cancer progression., PMID:39541298
Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism., PMID:39524871
Siglec-15 expression in diffuse gliomas and its correlation with MRI morphologic features and apparent diffusion coefficient., PMID:39434541
Aptamer-based Immune Checkpoint Inhibition for Cancer Immunotherapy., PMID:39417693
Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer., PMID:39301699
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion., PMID:38988824
Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor., PMID:38849345
The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma., PMID:38725348
Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer., PMID:38652971
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis., PMID:38252825
Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats., PMID:38130761
Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy., PMID:37955317
Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis., PMID:37607544
Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia., PMID:37465593
Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b., PMID:37311743
Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma., PMID:37234161
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions., PMID:37103472
Histochemical assessment on osteoclasts in long bones of toll-like receptor 2 (TLR2) deficient mice., PMID:37088152
Histochemical assessment of osteoclast-like giant cells in Rankl-/- mice., PMID:37088151
Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy., PMID:36648946
Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancer., PMID:36159823
Obesity accelerates immune evasion of non-small cell lung carcinoma via TFEB-dependent upregulation of Siglec-15 and glycolytic reprogramming., PMID:36150633
Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway., PMID:36105484
Single-cell roadmap of human gonadal development., PMID:35794482
Corrigendum to "A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME" [Pharmacol. Res. 181 (2022) 106269]., PMID:35773057
Screening and Identification of a Novel Anti-Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity., PMID:35764384
Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma., PMID:35729260
[Study on the effect and mechanisms of SIGLEC-15 on laryngeal squamous cell carcinoma]., PMID:35725316
A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME., PMID:35605813
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer., PMID:35581307
Development of an immunohistochemical assay for Siglec-15., PMID:35459795
Long Noncoding RNA TUG1 Inhibits Tumor Progression through Regulating Siglec-15-Related Anti-Immune Activity in Hepatocellular Carcinoma., PMID:35237695
Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer., PMID:35151947
Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma., PMID:35083884
SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer., PMID:35077803
High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy., PMID:34988324
Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis., PMID:34943606
Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer., PMID:34893976
An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion., PMID:34719673
For research use only. Not for human or drug use.
